{"slug":"hypotheses","open_questions":[{"id":"open_question-b7651f5b-1fcc-46e9-8110-4d69b06c42d9","title":"What molecular pathways link different proteinopathies?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-93c6bab9-f413-4a21-b43a-03531ac562fe","title":"Can we prevent secondary proteinopathy after primary diagnosis?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-a5322346-17bb-4f1b-8fab-ba9e702309ba","title":"What determines which protein pathology develops first?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-ecb80fe3-243b-4929-9554-1892c5c2f4a8","title":"How do we model co-pathology in experimental systems?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-232de8b4","title":"Strain-specific targeting","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-4892d91a","title":"Early intervention","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-24c5bcee","title":"Biomarker development","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-hypotheses-proteinopathic-processes-spread-through-brain-adb20a00","title":"Combination approaches","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-e7abc851-8ce3-480b-835a-369d76c86bc6","title":"What is the optimal timing for neurotrophin intervention relative to disease stage?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-dc094973-c93f-4225-8d1f-ccd5005c66d0","title":"Can combination therapy (GDNF + anti-α-syn) provide synergistic benefits?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-b4513284-52f5-4217-a4d1-ef2ddf04c626","title":"How do genetic subtypes (LRRK2, GBA, SNCA) affect neurotrophin response?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-242876d5-1f07-4666-82e2-2afe3571a457","title":"What are the long-term safety implications of sustained GDNF expression?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-65be8c41-e052-42d0-98f4-bfa504713186","title":"Can peripheral biomarkers predict CNS neurotrophin deficiency?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-6471b210-0fa3-430b-a0ba-af201961fc4a","title":"What is the minimum effective dose for different delivery methods?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-4b9da982-2b1b-4bf5-b50c-0b058ce8fa22","title":"Can biomarker panels identify ideal candidates for specific therapies?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-32b096d5-30df-4611-96ef-5f5ea86add77","title":"Does SG dysfunction precede alpha-synuclein pathology in humans?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-173a4067-8ac7-4769-b5a0-e0bb515cb9ac","title":"Can SG modulation slow disease progression in PD models?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-4dcfc292-0919-476f-a8e2-400cef297d14","title":"What are the specific vulnerabilities of dopaminergic neurons to SG pathology?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-5a295a20-6e17-4167-8ec1-8eed0e04a9be","title":"How do genetic risk factors (LRRK2, GBA, SNCA) interact with SG pathways?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5},{"id":"open_question-27d9a494-acea-46e5-95a3-a9ee68027a87","title":"How does age affect neurotrophin therapy response?","importance_elo":1500,"status":"open","potential_impact_score":0.5,"tractability_score":0.5}],"open_questions_total":20,"knowledge_gaps":[],"gap_count":0,"landscape":null,"hypothesis_count":0,"personas":[{"id":"christof-koch","name":"Christof Koch","type":"debater","icon":"🌀","color":"#5c6bc0","debate_count":1},{"id":"rui-costa","name":"Rui Costa","type":"debater","icon":"🏃","color":"#ef5350","debate_count":1},{"id":"xiaojun-li","name":"Xiaojun Li","type":"debater","icon":"🔬","color":"#8d6e63","debate_count":0},{"id":"pete-skene","name":"Pete Skene","type":"debater","icon":"🔬","color":"#8d6e63","debate_count":0},{"id":"ed-lein","name":"Ed Lein","type":"debater","icon":"🧠","color":"#4fc3f7","debate_count":0},{"id":"clinical_trialist","name":"Clinical Trialist","type":"reviewer","icon":"📋","color":"#4dd0e1","debate_count":0},{"id":"sud-pinglay","name":"Sud Pinglay","type":"debater","icon":"🧬","color":"#26a69a","debate_count":0},{"id":"jay-shendure","name":"Jay Shendure","type":"debater","icon":"🧪","color":"#ffa726","debate_count":0},{"id":"medicinal_chemist","name":"Medicinal Chemist","type":"builder","icon":"🧪","color":"#aed581","debate_count":0}]}